# Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

> **NCT00017394** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (actual)

## Conditions studied

- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** vinorelbine tartrate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00017394
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017394, "Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00017394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*